Zeteo Tech Expands IP Portfolio of Mass Spectrometry Technology

Zeteo Tech Inc. has been issued a new U.S. patent that further protects its technology to rapidly analyze bacteria, viruses, and toxins.

Patent No. 11658021, “Systems and Methods of Rapid and Autonomous Detection of Aerosol Particles,” is the fourth U.S. patent for Zeteo Tech on mass spectrometry technology, (three granted and one allowed). In addition, Zeteo Tech has 12 mass spectrometry-related foreign patents, (11 granted and one allowed).

“This latest patent adds to Zeteo Tech’s IP portfolio protecting our technology that can perform rapid analysis of biological aerosols, including bacteria, viruses, and toxins,” Zeteo Tech President/CEO Dr. Wayne Bryden said. “Our mission is to collaborate with partners to commercialize our technology in order to help protect life and critical infrastructure by enabling rapid detection and accelerated initiation of emergency management protocols. For example, the system is capable of rapidly detecting new biological threats and being deployed in potential pandemic scenarios, similar to COVID-19.”

Using Zeteo Tech’s patented “point-of-need” portable threat detection system, air samples can be automatically collected and analyzed for chemical and biological aerosolized threat agents, including bacteria, viruses, toxins, and chemicals such as fentanyl. The system’s sophisticated microfluidics, control architecture, threat agent library, and AI/ML software enable threat identification with high specificity and sensitivity within just a few minutes. 
 
Zeteo Tech has licensed its portable threat detection technology to Albuquerque-based bioaerosol surveillance company BioFlyte. This agreement allows BioFlyte to use the technology for environmental sampling, detection, monitoring, and identification of chemical and biological threats within the defense and security market. BioFlyte is partnering with financial institutions, government organizations, like the Department of Defense, and airports, such as the Pittsburgh International Airport, to test and demonstrate the capabilities of its BioTOF z200 system.
 
“BioFlyte emerged from Zeteo Tech’s portfolio of proprietary mass spectrometry technology, and our ongoing strategic partnership has been critical for our growth,” BioFlyte CEO Todd Sickles stated. “With Zeteo’s support, BioFlyte is commercializing this rapid threat detection technology to protect people, critical infrastructure, and more.”
 
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a new class of fieldable biological mass spectrometers. Zeteo’s instruments identify airborne microbes, proteins, and lipids, and can be used to screen for infectious disease and other biothreats. Its patented and patent-pending time of flight mass spectrometry technology, digitalMALDI, enables fully automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being currently deployed for biodefense applications.